vs
ACNB CORP（ACNB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ACNB CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$47.2M vs $35.5M），ACNB CORP净利率更高（22.9% vs -304.2%，领先327.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 42.2%），ACNB CORP自由现金流更多（$52.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 22.1%）
ACNB集团是总部位于美国宾夕法尼亚州的金融控股公司，提供零售及商业银行服务、财富管理、信托服务、财产及意外伤害保险等金融产品，主要服务宾夕法尼亚州中南部、马里兰州北部的当地居民及中小企业客户。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ACNB vs RXRX — 直观对比
营收规模更大
ACNB
是对方的1.3倍
$35.5M
营收增速更快
RXRX
高出639.5%
42.2%
净利率更高
ACNB
高出327.1%
-304.2%
自由现金流更多
ACNB
多$99.9M
$-47.3M
两年增速更快
RXRX
近两年复合增速
22.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.2M | $35.5M |
| 净利润 | $10.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 27.9% | -304.8% |
| 净利率 | 22.9% | -304.2% |
| 营收同比 | 42.2% | 681.7% |
| 净利润同比 | 63.8% | 39.6% |
| 每股收益（稀释后） | $1.10 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACNBRXRX
| Q4 25 | $47.2M | $35.5M | ||
| Q3 25 | $50.9M | $5.2M | ||
| Q2 25 | $50.3M | $19.2M | ||
| Q1 25 | $43.5M | $14.7M | ||
| Q4 24 | $33.2M | $4.5M | ||
| Q3 24 | $34.1M | $26.1M | ||
| Q2 24 | $33.3M | $14.4M | ||
| Q1 24 | $31.6M | $13.8M |
净利润ACNBRXRX
| Q4 25 | $10.8M | $-108.1M | ||
| Q3 25 | $14.9M | $-162.3M | ||
| Q2 25 | $11.6M | $-171.9M | ||
| Q1 25 | $-272.0K | $-202.5M | ||
| Q4 24 | $6.6M | $-178.9M | ||
| Q3 24 | $7.2M | $-95.8M | ||
| Q2 24 | $11.3M | $-97.5M | ||
| Q1 24 | $6.8M | $-91.4M |
毛利率ACNBRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率ACNBRXRX
| Q4 25 | 27.9% | -304.8% | ||
| Q3 25 | 37.2% | -3327.6% | ||
| Q2 25 | 29.7% | -916.8% | ||
| Q1 25 | -1.3% | -1297.9% | ||
| Q4 24 | 24.8% | -4042.4% | ||
| Q3 24 | 27.6% | -377.1% | ||
| Q2 24 | 42.8% | -697.4% | ||
| Q1 24 | 26.9% | -698.4% |
净利率ACNBRXRX
| Q4 25 | 22.9% | -304.2% | ||
| Q3 25 | 29.2% | -3135.3% | ||
| Q2 25 | 23.2% | -894.2% | ||
| Q1 25 | -0.6% | -1373.3% | ||
| Q4 24 | 19.9% | -3935.5% | ||
| Q3 24 | 21.1% | -367.5% | ||
| Q2 24 | 33.9% | -676.6% | ||
| Q1 24 | 21.4% | -662.4% |
每股收益（稀释后）ACNBRXRX
| Q4 25 | $1.10 | $-0.17 | ||
| Q3 25 | $1.42 | $-0.36 | ||
| Q2 25 | $1.11 | $-0.41 | ||
| Q1 25 | $-0.03 | $-0.50 | ||
| Q4 24 | $0.77 | $-0.56 | ||
| Q3 24 | $0.84 | $-0.34 | ||
| Q2 24 | $1.32 | $-0.40 | ||
| Q1 24 | $0.80 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $65.6M | $743.3M |
| 总债务越低越好 | $255.4M | $9.6M |
| 股东权益账面价值 | $420.0M | $1.1B |
| 总资产 | $3.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.61× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ACNBRXRX
| Q4 25 | $65.6M | $743.3M | ||
| Q3 25 | $102.1M | $659.8M | ||
| Q2 25 | $103.1M | $525.1M | ||
| Q1 25 | $123.6M | $500.5M | ||
| Q4 24 | $47.3M | $594.4M | ||
| Q3 24 | $58.1M | $427.6M | ||
| Q2 24 | $86.3M | $474.3M | ||
| Q1 24 | $53.1M | $296.3M |
总债务ACNBRXRX
| Q4 25 | $255.4M | $9.6M | ||
| Q3 25 | $255.4M | $11.9M | ||
| Q2 25 | $255.4M | $14.2M | ||
| Q1 25 | $255.3M | $16.4M | ||
| Q4 24 | $255.3M | $19.0M | ||
| Q3 24 | $255.3M | $20.5M | ||
| Q2 24 | $255.3M | $22.9M | ||
| Q1 24 | $255.3M | — |
股东权益ACNBRXRX
| Q4 25 | $420.0M | $1.1B | ||
| Q3 25 | $408.6M | $1.0B | ||
| Q2 25 | $395.2M | $919.1M | ||
| Q1 25 | $386.9M | $933.9M | ||
| Q4 24 | $303.3M | $1.0B | ||
| Q3 24 | $306.8M | $524.6M | ||
| Q2 24 | $289.3M | $584.4M | ||
| Q1 24 | $279.9M | $401.2M |
总资产ACNBRXRX
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.3B | $1.4B | ||
| Q2 25 | $3.3B | $1.3B | ||
| Q1 25 | $3.3B | $1.3B | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $2.4B | $726.5M | ||
| Q2 24 | $2.5B | $775.9M | ||
| Q1 24 | $2.4B | $557.8M |
负债/权益比ACNBRXRX
| Q4 25 | 0.61× | 0.01× | ||
| Q3 25 | 0.62× | 0.01× | ||
| Q2 25 | 0.65× | 0.02× | ||
| Q1 25 | 0.66× | 0.02× | ||
| Q4 24 | 0.84× | 0.02× | ||
| Q3 24 | 0.83× | 0.04× | ||
| Q2 24 | 0.88× | 0.04× | ||
| Q1 24 | 0.91× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $52.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 111.4% | -133.1% |
| 资本支出强度资本支出/营收 | 2.3% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.96× | — |
| 过去12个月自由现金流最近4个季度 | $92.2M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ACNBRXRX
| Q4 25 | $53.6M | $-46.1M | ||
| Q3 25 | $23.2M | $-117.4M | ||
| Q2 25 | $17.8M | $-76.4M | ||
| Q1 25 | $-71.0K | $-132.0M | ||
| Q4 24 | $39.8M | $-115.4M | ||
| Q3 24 | $13.6M | $-59.2M | ||
| Q2 24 | $9.7M | $-82.2M | ||
| Q1 24 | $10.8M | $-102.3M |
自由现金流ACNBRXRX
| Q4 25 | $52.6M | $-47.3M | ||
| Q3 25 | $22.8M | $-117.6M | ||
| Q2 25 | $17.6M | $-79.6M | ||
| Q1 25 | $-730.0K | $-133.8M | ||
| Q4 24 | $38.8M | $-116.7M | ||
| Q3 24 | $13.3M | $-63.8M | ||
| Q2 24 | $9.4M | $-83.4M | ||
| Q1 24 | $10.7M | $-109.0M |
自由现金流率ACNBRXRX
| Q4 25 | 111.4% | -133.1% | ||
| Q3 25 | 44.7% | -2272.5% | ||
| Q2 25 | 35.0% | -413.9% | ||
| Q1 25 | -1.7% | -907.4% | ||
| Q4 24 | 117.0% | -2567.7% | ||
| Q3 24 | 39.1% | -244.6% | ||
| Q2 24 | 28.3% | -578.5% | ||
| Q1 24 | 33.9% | -789.9% |
资本支出强度ACNBRXRX
| Q4 25 | 2.3% | 3.5% | ||
| Q3 25 | 0.8% | 4.7% | ||
| Q2 25 | 0.4% | 16.4% | ||
| Q1 25 | 1.5% | 12.4% | ||
| Q4 24 | 2.9% | 28.6% | ||
| Q3 24 | 0.7% | 17.5% | ||
| Q2 24 | 0.9% | 8.2% | ||
| Q1 24 | 0.2% | 48.2% |
现金转化率ACNBRXRX
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
